Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$66.21

21.415 (47.81%)

09:47
08/29/18
08/29
09:47
08/29/18
09:47

Glaukos rises 47.3%

Glaukos is up 47.3%, or $21.20 to $66.00.

  • 05

    Sep

GKOS Glaukos
$66.21

21.415 (47.81%)

08/24/18
WELS
08/24/18
NO CHANGE
Target $50
WELS
Outperform
Ivantis counterclaim against Glaukos looks weak, says Wells Fargo
Following a review by his firm's patent consultant, Wells Fargo analyst Larry Biegelsen says Ivantis' counterclaim, alleging that Glaukos' new iStent inject product will infringe three Ivantis patents, appears weak. The Ivantis patents very specifically add a detail about the placement of the shunt, which reads as "too straightforward" or "obvious," the patent consultant told the analyst. As such, he believes the patents will ultimately be found invalid. Biegelsen keeps an Outperform rating on Glaukos with a $50 price target.
08/29/18
WBLR
08/29/18
NO CHANGE
WBLR
Outperform
CyPass market removal a 'clear positive' for Glaukos, says William Blair
William Blair analyst Brian Weinstein believes Alcon's voluntary global market withdrawal of its CyPass Micro-Stent for surgical glaucoma is a "clear positive for near-term numbers" at Glaukos (GKOS). If Glaukos' iStent takes all of the CyPass market share while it is off the market, the company could add as much as $50M in the U.S. alone to its 2019 total revenue of around $186M, Weinstein tells investors in a research note, while admitting this is a bullish stance. The analyst thinks the news this morning from Alcon should be viewed as a positive for Glaukos, as a major part of the short thesis was on competition in the core iStent market, mainly from Alcon. He keeps an Outperform rating on Glaukos shares.
08/29/18
PIPR
08/29/18
NO CHANGE
Target $55
PIPR
Overweight
Piper sees CyPass withdrawal as 'major boon' for Glaukos, ups target to $55
Piper Jaffray analyst Matt O'Brien views Alcon's immediate withdrawal of its CyPass stent for the treatment of glaucoma on safety concerns from a recently completed clinical study as a "major boon" for Glaukos (GKOS). The analyst suspects it will be several quarters before CyPass comes back to the market, with with a much narrower indication. This is a "major positive" for Glaukos as most of the clinicians using CyPass had been or are still using iStent from Glaukos, O'Brien tells investors in a research note. He anticipates many clinicians will quickly shift their volumes back to iSten, yielding "significant incremental revenues." Based on this morning's news, the analyst raised his price target for Glaukos shares to $55 from $46. He encourages investors to start or build positions in the name.
08/29/18
SPHN
08/29/18
NO CHANGE
Target $57
SPHN
Overweight
Glaukos price target raised to $57 at Stephens after Novartis withdraws CyPass
Stephens analyst Chris Cooley raised his price target on Glaukos (GKOS) shares to $57 from $50 after Novartis' (NVS) Alcon unit withdrew the CyPass micro-stent from the market due to safety concerns. He estimates $40M-$50M in annual sales are now "in play" and see Glaukos as the most likely beneficiary, Cooley tells investors. He maintains an Overweight rating on Glaukos shares, which are up $17.35, or 39%, to $62.15 in pre-market trading.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$39.82

5.43 (15.79%)

13:59
04/23/19
04/23
13:59
04/23/19
13:59
Recommendations
Twitter analyst commentary  »

Twitter price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 20

    May

ADNT

Adient

$25.11

-0.43 (-1.68%)

13:55
04/23/19
04/23
13:55
04/23/19
13:55
Options
Adient put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

TNXP

Tonix Pharmaceuticals

$2.29

-0.035 (-1.51%)

13:54
04/23/19
04/23
13:54
04/23/19
13:54
Hot Stocks
Tonix Pharmaceuticals says USAMMDA exercising right to terminate CRADA »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

TNXP

Tonix Pharmaceuticals

$2.29

-0.035 (-1.51%)

13:52
04/23/19
04/23
13:52
04/23/19
13:52
Hot Stocks
Breaking Hot Stocks news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AGN

Allergan

$142.87

2.6 (1.85%)

, TEVA

Teva

$15.14

0.435 (2.96%)

13:50
04/23/19
04/23
13:50
04/23/19
13:50
Conference/Events
Piper Jaffray specialty pharma analysts to hold analyst/industry conference call »

Specialty Pharmaceuticals…

AGN

Allergan

$142.87

2.6 (1.85%)

TEVA

Teva

$15.14

0.435 (2.96%)

ALDR

Alder Biopharmaceuticals

$13.55

0.78 (6.11%)

AMGN

Amgen

$180.01

3.81 (2.16%)

BHVN

Biohaven Pharmaceutical

$63.34

2.39 (3.92%)

LLY

Eli Lilly

$117.60

2.16 (1.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

  • 21

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

TWTR

Twitter

$39.95

5.56 (16.17%)

13:44
04/23/19
04/23
13:44
04/23/19
13:44
Recommendations
RBC 'more constructive' on Twitter post results, boosts price target to $38 »

In a post-earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 20

    May

BRFS

BRF S.A.

$7.54

0.44 (6.20%)

13:40
04/23/19
04/23
13:40
04/23/19
13:40
Options
Renewed call buying in BRF SA as shares rally 6.5% »

Renewed call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PW

Power REIT

$5.74

-0.075 (-1.29%)

13:39
04/23/19
04/23
13:39
04/23/19
13:39
Hot Stocks
Cascadilla Capital Partners urges sale or liquidation of Power REIT »

Todd Merkle, Managing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$31.44

1.21 (4.00%)

13:36
04/23/19
04/23
13:36
04/23/19
13:36
Recommendations
PulteGroup analyst commentary  »

PulteGroup price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 08

    May

MBRX

Moleculin Biotech

$1.60

-1.37 (-46.13%)

13:35
04/23/19
04/23
13:35
04/23/19
13:35
Hot Stocks
Sabby Management reports 7.14% passive stake in Moleculin Biotech »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LMT

Lockheed Martin

$336.62

21.38 (6.78%)

13:31
04/23/19
04/23
13:31
04/23/19
13:31
Hot Stocks
Lockheed Martin receives $362M contract for MLRS launchers »

The U.S. Army awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 29

    May

  • 05

    Jun

13:30
04/23/19
04/23
13:30
04/23/19
13:30
General news
Treasury Action: yields remain lower after a well received 2-year auction »

Treasury Action: yields…

TCEHY

Tencent

$0.00

(0.00%)

, KKR

KKR

$23.76

0.33 (1.41%)

13:28
04/23/19
04/23
13:28
04/23/19
13:28
Periodicals
Epic workers describe 'Fortnite' working environment as toxic, Polygon says »

Current and former…

TCEHY

Tencent

$0.00

(0.00%)

KKR

KKR

$23.76

0.33 (1.41%)

DIS

Disney

$133.00

1.3 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 08

    May

  • 15

    May

  • 11

    Jun

TSLA

Tesla

$264.55

1.65 (0.63%)

13:26
04/23/19
04/23
13:26
04/23/19
13:26
Hot Stocks
Tesla electric vehicle challenger Lucid Motors appoints Peter Rawlinson as CEO »

Electric car start-up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

PAGS

PagSeguro Digital

$26.03

0.375 (1.46%)

13:25
04/23/19
04/23
13:25
04/23/19
13:25
Options
PagSeguro Digital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.37

4.14 (1.52%)

, CRM

Salesforce

$160.44

1.69 (1.06%)

13:25
04/23/19
04/23
13:25
04/23/19
13:25
Conference/Events
Stephens eCommerce analysts to hold an analyst/industry conference call »

Analysts provide an…

ADBE

Adobe

$276.37

4.14 (1.52%)

CRM

Salesforce

$160.44

1.69 (1.06%)

SHOP

Shopify

$223.04

-1.28 (-0.57%)

SAP

SAP

$114.13

0.36 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 30

    Apr

  • 07

    May

  • 08

    May

  • 03

    Jun

  • 23

    Jun

13:25
04/23/19
04/23
13:25
04/23/19
13:25
Conference/Events
The Board of Governors of the Federal Reserve System to hold a meeting »

The Board of Governors of…

DNLI

Denali Therapeutics

$24.10

-0.74 (-2.98%)

13:25
04/23/19
04/23
13:25
04/23/19
13:25
Conference/Events
Denali Therapeutics participates in a conference call with JPMorgan »

SMid Biotech Analyst Fye…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
04/23/19
04/23
13:17
04/23/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
04/23/19
04/23
13:16
04/23/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
04/23/19
04/23
13:15
04/23/19
13:15
General news
Treasury's $40 B 2-year auction was well received »

Treasury's $40 B…

UBS

UBS

$13.15

-0.11 (-0.83%)

, DB

Deutsche Bank

$8.58

-0.175 (-2.00%)

13:12
04/23/19
04/23
13:12
04/23/19
13:12
Periodicals
UBS, Deutsche Bank asset management units in serious merger talks, FT says »

The asset management…

UBS

UBS

$13.15

-0.11 (-0.83%)

DB

Deutsche Bank

$8.58

-0.175 (-2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 29

    Apr

  • 20

    May

  • 03

    Jun

GD

General Dynamics

$182.49

5.43 (3.07%)

13:10
04/23/19
04/23
13:10
04/23/19
13:10
Options
Bullish spread in General Dynamics as shares rally ahead of earnings »

Bullish spread in General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 29

    May

13:07
04/23/19
04/23
13:07
04/23/19
13:07
General news
2-Yr Note Auction Coupon Rate data reported »

2-Yr Note Auction Coupon…

13:07
04/23/19
04/23
13:07
04/23/19
13:07
General news
2-Yr Note Auction Total Amount data reported »

2-Yr Note Auction Total…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.